0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IFN-beta

IFN-beta

IFN-beta Molecule Information

Name:Interferon beta
Target Synonym:IFNB;IFN-beta;Fibroblast interferon;IFNB1;IFB
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:19
Lastest Research Phase:Approved

IFN-beta Molecule Synonym Name

IFNB1,Interferon beta,IFN-beta,IFB,IFNB

IFN-beta Molecule Background

Human type I interferons (IFNs) are a large subgroup of interferon proteins that help regulate the activity of the immune system. Interferons bind to interferon receptors. All type I IFNs bind to a specific cell surface receptor complex known as the IFN-¦Á receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains. The IFN-¦Â proteins are produced in large quantities by fibroblasts. They have antiviral activity that is involved mainly in innate immune response. Two types of IFN-¦Â have been described, IFN-¦Â1 (IFNB1) and IFN-¦Â3 (IFNB3) (a gene designated IFN-¦Â2 is actually IL-6). IFN-¦Â1 is used as a treatment for multiple sclerosis as it reduces the relapse rate. Furthermore, IFN-¦Â1 can bind to a IFNAR1-IFNAR2 heterodimeric receptor, and can also function with IFNAR1 alone and independently of Jak-STAT pathways.

IFN-beta References

IFN-beta Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Interferon beta-1a biosimilar (Probiomed S.A) Approved Probiomed Multiple sclerosis (MS) Details
Interferon beta-1b biosimilar (InSight Biopharmaceuticals) Approved InSight Biopharmaceuticals Multiple sclerosis (MS) Details
Interferon beta-1a biosimilar (InSight Biopharmaceuticals) Approved InSight Biopharmaceuticals Multiple sclerosis (MS) Details

IFN-beta Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
EMZ-701 EMZ-701 Phase Ⅱ Transition therapeutics Multiple sclerosis (MS) Details
VSV-IFNbeta-NIS Phase Ⅱ Vyriad Solid tumours, Colorectal cancer Details
Gene-activated beta-interferon (Shire Human Genetic Therapies) Preclinical Shire Multiple sclerosis (MS) Details
Interferon beta-1a biosimilar (Harvest Moon Pharmaceuticals) Phase Not Specified Harvest Moon Multiple sclerosis (MS) Details
Interferon beta-1a biosimilar (Axxo) Phase Not Specified AXXO Multiple sclerosis (MS) Details
TA-383 TA-383 Phase Ⅱ Mitsubishi Tanabe Pharma Rheumatoid arthritis (RA) Details
VSV-hIFNbeta-NIS (University of Tennessee) Phase Ⅰ The University of Tennessee, Mayo Clinic Endometrial cancer, Multiple myeloma (MM), Acute myeloid Leukemia (AML), T cell lymphoma Details
PF-06823859 PF-06823859,PF 06823859,PF06823859 Phase Ⅱ Pfizer Systemic lupus erythematosus, Dermatomyositis Details
ARX-424 (Ambrx) ARX-424 Phase Ⅰ Ambrx, Merck Serono Multiple sclerosis (MS) Details
IFN-b gene therapy (Nagoya University) IAB-1; pDRSV- IFN-BETA,IAB 1; pDRSV IFN BETA,IAB1 Phase Ⅰ Nagoya University Malignant glioma Details
Peginterferon beta-1a (CinnaGen) Phase Ⅲ CinnaGen Multiple sclerosis (MS) Details
ME-3738 ME-3738 Phase Ⅱ Meiji Seika Pharma HCV infection Details
IFNAR2 IFNAR-2; r-hIFNAR2alpha Phase Ⅱ Merck Serono, Weizmann Institute of Science, Yeda Pharma Autoimmune diseases, Multiple sclerosis (MS) Details
Interferon beta-1a (Nastech) Phase Ⅰ Nastech Pharmaceutical Company Multiple sclerosis (MS) Details
Multiple sclerosis therapies (Syntonix Pharmaceuticals) Preclinical Biogen Idec Multiple sclerosis (MS) Details
Interferon beta-1b biosimilar (Axxo) Phase Not Specified AXXO Multiple sclerosis (MS) Details
Interferon beta XL (Flamel Technologies) Phase Ⅰ Avadel Pharmaceuticals, Merck Serono Multiple sclerosis (MS) Details
Interferon beta-1a (University Health Network) Phase Ⅱ University Health Network Ebola virus disease (EVD) Details
ARX-1088 ARX-1088 Preclinical UMeWorld Viral infections, Multiple sclerosis (MS) Details

This web search service is supported by Google Inc.

totop